Janssen Scientific Affairs, LLC, Raritan, New Jersey, USA.
BMC Psychiatry. 2011 Oct 14;11:168. doi: 10.1186/1471-244X-11-168.
Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care. This analysis examined health care resource utilization from a 24-month observational study of patients with schizophrenia initiated on risperidone long-acting therapy (RLAT).
Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE) was a 24-month observational study designed to examine real-world treatment outcomes by prospectively following patients with schizophrenia initiated on RLAT. At baseline visit, prior hospitalization and ER visit dates were obtained for the previous 12 months and subsequent hospitalization visit dates were obtained at 3-month visits, if available. The health care resource utilization outcomes measures observed in this analysis were hospitalizations for any reason, psychiatric-related hospitalizations, and emergency room (ER) visits. Incidence density analysis was used to assess pre-event and postevent rates per person-year (PY).
The primary medical resource utilization analysis included 435 patients who had a baseline visit, ≥1 postbaseline visits after RLAT initiation, and valid hospitalization dates. The number of hospitalizations and ER visits per PY declined significantly (p < .0001) after initiation with RLAT. A 41% decrease (difference of -0.29 hospitalizations per PY [95% CI: -0.39 to -0.18] from baseline) in hospitalizations for any reason, a 56% decrease (a difference of -0.35 hospitalizations per PY [95% CI: -0.44 to -0.26] from baseline) in psychiatric-related hospitalizations, and a 40% decrease (-0.26 hospitalizations per PY [95% CI: -0.44 to -0.10] from baseline) in ER visits were observed after the baseline period. The percentage of psychiatric-related hospitalizations decreased significantly after RLAT initiation, and patients had fewer inpatient hospitalizations and ER visits (all p < .0001).
The results suggest that treatment with RLAT may result in decreased hospitalizations for patients with schizophrenia.
ClinicalTrials.gov: NCT00246194.
精神分裂症是一种慢性精神健康障碍，与住院人数增加以及门诊服务和长期护理的过度利用有关。这项分析检查了接受利培酮长效治疗（RLAT）的精神分裂症患者的 24 个月观察性研究中的医疗资源利用情况。
精神分裂症结局利用复发和临床评估（SOURCE）是一项 24 个月的观察性研究，旨在通过前瞻性随访接受 RLAT 治疗的精神分裂症患者，来检查真实世界的治疗结果。在基线访视时，获得了过去 12 个月的先前住院和急诊就诊日期，并且如果可用，则在 3 个月访视时获得了随后的住院就诊日期。在这项分析中观察到的医疗资源利用结果测量包括因任何原因住院、与精神科相关的住院和急诊就诊。发病率密度分析用于评估每患者年（PY）的预事件和后事件率。
主要医疗资源利用分析包括 435 名患者，他们进行了基线访视，在 RLAT 起始后至少有 1 次基线后访视，并且有有效的住院日期。在 RLAT 起始后，住院和急诊就诊次数的 PY 显著下降（p <.0001）。任何原因的住院次数减少了 41%（从基线到 PY 的差异为-0.29 次住院[95%CI：-0.39 至 -0.18]），与精神科相关的住院次数减少了 56%（从基线到 PY 的差异为-0.35 次住院[95%CI：-0.44 至 -0.26]），急诊就诊次数减少了 40%（从基线到 PY 的差异为-0.26 次住院[95%CI：-0.44 至 -0.10]）。在 RLAT 起始后，与精神科相关的住院次数百分比显著下降，患者的住院次数和急诊就诊次数减少（均 p <.0001）。
结果表明，RLAT 治疗可能会减少精神分裂症患者的住院次数。
ClinicalTrials.gov：NCT00246194。
